Lenalidomide in multiple myeloma

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 4, 2007, Pages 717-735

  Thomas, Sheeba K ^a   Richards, Tiffany A ^a   Weber, Donna M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

dexamethasone; immunomodulatory agents; lenalidomide; myeloma; thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; AMOXICILLIN; BORTEZOMIB; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; RAPAMYCIN; THALIDOMIDE; VINCRISTINE; WARFARIN;

ACNE; AMYLOIDOSIS; ANEMIA; ANXIETY; APOPTOSIS; AREA UNDER THE CURVE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CELL; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOMODULATION; INFECTION; KIDNEY FAILURE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEASLES LIKE RASH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; URTICARIA; VIRUS REACTIVATION;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALIDOMIDE;

EID: 36749041340     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.09.002     Document Type: Review

References (86)

1. Alexanian R., Barlogie B., and Tucker S. VAD-based regimens as primary treatment for multiple myeloma. American Journal of Hematology 33 2 (1990) 86-89
2. Alexanian R., Bergsagel D.E., Migliore P.J., et al. Melphalan therapy for plasma cell myeloma. Blood 31 1 (1968) 1-10
3. Alexanian R., Dimopoulos M.A., Delasalle K., et al. Primary dexamethasone treatment of multiple myeloma. Blood 80 4 (1992) 887-890
4. Alexanian R., Haut A., Khan A.U., et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. The Journal of the American Medical Association 208 9 (1969) 1680-1685
5. Alexanian R., Weber D., Giralt S., et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplantation 27 10 (2001 May) 1037-1043
6. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine 348 19 (2003 May 8) 1875-1883
7. Alexanian R., Weber D., Anagnostopoulos A., et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology 40 4 supplement 4 (2003) 3-7
8. Chanan-Khan A., and Miller K.C. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leukemia & Lymphoma 46 7 (2005 Jul) 1103-1104
9. Dimopoulos M.A., Zervas K., Kouvatseas G., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology 12 7 (2001 July 1) 991-995
10. Orlowski RZ, Peterson BL, Sanford B et al. Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 797.
11. Palumbo A, Ambrosini MT, Benevolo G et al. Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 407.
12. Popat R, Williams C, Cook M et al. A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3542.
13. Chanan-Khan A.A., Miller K.C., McCarthy P., et al. VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) is an effective initial therapy with high response rates for patients with treatment naïve multiple myeloma (MM). Blood 104 (2004)
14. Hussein M.A., Baz R., Srkalovic G., et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. [see comment]. Mayo Clinic Proceedings 81 7 (2006) 889-895
15. Jagannath S., Durie B.G., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology 129 6 (2005) 776-783
16. Mateos M.-V., Hernandez J.-M., Hernandez M.-T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 108 7 (2006 October 1) 2165-2172
17. Oakervee H.E., Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology 129 6 (2005) 755-762
18. Offidani M., Corvatta L., Piersantelli M.-N., et al. Thalidomide, dexamethasone, pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 108 (2006) 2159-2164
19. Wang M, Delasalle K, Giralt S et al. Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 784.
20. Zervas K., Dimopoulos M.A., Hatzicharissi E., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Annals of Oncology 15 1 (2004) 134-138
21. Jakubowiak AJ, Al-Zoubi A, Kendall T et al. High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade(V)), Doxil(D), Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT). ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3093.
22. Palumbo A., Bertola A., Musto P., et al. Oral melphalan, prednisone, thalidomide for newly diagnosed patients with myeloma. Cancer 104 (2005) 1428-1433
23. Boulin M., Blanchet F., Isambert N., et al. Thalidomide with or without dexamethasone for refractory multiple myeloma. Therapie 57 6 (2002) 524-529
24. Zangari M., Barlogie B., Jacobson J., et al. VTD regimen comprising Velcade (V) + Thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 102 11 (2003)
25. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 9513 (2006) 825-831
26. Jakubowiak A., Friedman J., Kendall T., et al. A phase II study of combination of bortezomib, liposomal doxorubin, dexamethasone (VDD) as first line therapy for multiple myeloma. Journal of Clinical Oncology 24 18S (2006)
27. Weber D., Rankin K., Gavino M., et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology 21 (2003) 16-19
28. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [see comment]. New England Journal of Medicine 352 24 (2005 Jun 16) 2487-2498
29. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. [see comment]. New England Journal of Medicine 348 26 (2003) 2609-2617
30. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. [see comment]. Journal of Clinical Oncology 24 3 (2006) 431-436
31. Rajkumar S.V., Hussein M., Catalano J., et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma 108 (2006) 795
32. Jagannath S, Durie BGM, Wolf JL et al. Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 796.
33. Anderson K., Richardson P., Chanan-Khan A., et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study. Journal of Clinical Oncology 24 18S (2006)
34. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. [see comment]. Blood 106 13 (2005) 4050-4053
35. Knight R. IMiDs: a novel class of immunomodulators. Seminars In Oncology 32 4 supplement 5 (2005) S24-S30
36. Lacy M., Gertz M., Dispenzieri A., et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, survival. Blood 108 (2006)
37. Richardson P, Jagannath S, Hussein M et al. A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 1565.
38. Richardson P.G., Blood E., Mitsiades C.S., et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108 10 (2006) 3458-3464
39. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). Journal of Clinical Oncology 24 18S (2006)
40. Zangari M T.G., Zeldis J., Eddlemon P., et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (mm) patients who relapse after high dose chemotherapy (HDCT). Blood (2001) 775a
41. Dispenzieri A., Lacy M.Q., Zeldenrust S.R., et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109 2 (2007 January 15) 465-470
42. Sanchorawala V., Wright D.G., Rosenzweig M., et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109 2 (2007 January 15) 492-496
43. Dimopoulos MA, Spencer A, Attal M et al. Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 6.
44. Weber D, Wang M, Chen C et al. Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3547.
45. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 9 (2002 October 16) 3063-3067
46. Muller G.W., Chen R., Huang S.Y., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorganic & Medicinal Chemistry Letters 9 11 (1999 Jun 7) 1625-1630
47. Anderson K.C. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Seminars in Hematology 42 4 supplement 4 (2005) S3-S8
48. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99 12 (2002) 4525-4530
49. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96 9 (2000) 2943-2950
50. Fujita E., Jinbo A., Matuzaki H., et al. Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochemical and Biophysical Research Communications 264 2 (1999) 550-555
51. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. Journal of Biological Chemistry 277 19 (2002) 16639-16647
52. Hideshima T., and Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer 2 12 (2002) 927-937
53. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 12 (2001) 1950-1961
54. Lentzsch S., LeBlanc R., Podar K., et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17 1 (2003) 41-44
55. Dredge K., Marriott J.B., Macdonald C.D., et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer 87 10 (2002) 1166
56. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine 341 21 (1999) 1565-1571
57. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. [see comment]. Blood 98 1 (2001) 210-216
58. Breitkreutz I., Tai Y., Li X., et al. Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: clinical implications. 2006 ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 24 18S (2006) 7606
59. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, overcomes drug resistance in human multiple myeloma cells. Cancer Research 61 7 (2001) 3071-3076
60. Raje N., Kumar S., Hideshima T., et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104 13 (2004 December 15) 4188-4193
61. Zeldis J.B., Williams B.A., Thomas S.D., et al. S.T.E.P.S., a comprehensive program for controlling and monitoring access to thalidomide. Clinical Therapeutics 21 2 (1999 Feb) 319-330
62. Knight R. Lenalidomide and venous thrombosis in multiple myeloma. The New England Journal of Medicine 354 19 (2006) 2079
63. Palumbo A, Falco P, Falcone A et al. Oral Revlimid(R) Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 800.
64. Zonder JA, Durie BGM, McCoy J et al. High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 3455.
65. Zonder J.A., Barlogie B., Durie B.G.M., et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108 1 (2006 July 1) 403-404
66. Rajkumar S., Jacobus S., Callander N., et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 25 18S (2007) LBA8025
67. Darabi K., Kantamnei S., and Wiernik P.H. Lenalidomide-induced warm autoimmune hemolytic anemia. Journal of Clinical Oncology 24 35 (2006 December 10) e59
68. Sviggum H.P., Davis M.D.P., Rajkumar S.V., et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Archives of Dermatology 142 10 (2006 October 1) 1298-1302
69. Kastritis E., and Dimopoulos M.A. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy 8 4 (2007) 497-509
70. Wang M, Knight R, Dimopoulos M et al. Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3553.
71. Knop S, Gerecke C, Topp MS et al. Lenalidomide (RevlimidTM), Adriamycin and Dexamethasone Chemotherapy (RAD) Is Safe and Effective in Treatment of Relapsed Multiple Myeloma - First Results of a German Multicenter Phase I/II Trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 408.
72. Baz R., Walker E., Karam M.A., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology 17 12 (2006) 1766-1771
73. Baz R., Li L., Kottke-Marchant K., et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. [see comment]. Mayo Clinic Proceedings 80 12 (2005) 1568-1574
74. Garcia-Sanz R., Gonzalez-Porras J.R., Hernandez J.M., et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18 4 (2004) 856-863
75. Morgan GJ, Schey S, Wu P et al. Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3555.
76. Richardson PG, Jagannath S, Avigan DE et al. Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 405.
77. Richardson P, Schlossman R, Munshi N et al. A Phase 1 Trial of Lenalidomide (REVLIMID(R)) with Bortezomib (VELCADE(R)) in Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 365.
78. Coleman M., Leonard J., Lyons L., et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leukemia & Lymphoma 43 9 (2002) 1777-1782
79. Niesvizky R., Jayabalan D., Furst J.R., et al. Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma. Journal of Clinical Oncology 24 18S (2006) 7545
80. Roy V, Leif BP, Jacob A et al. Melphalan (M), Prednisone (P) and Lenalidomide (R) Combination (MPR) for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3558.
81. Gertz M.A., and Rajkumar S.V. Primary systemic amyloidosis. Current Treatment Options in Oncology 3 (2002) 261-271
82. Skinner M., Anderson J., Simms R., et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, colchicine versus colchicine only. American Journal of Medicine 100 3 (1996) 290-298
83. Kyle R.A., Gertz M.A., Greipp P.R., et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, melphalan, prednisone, colchicine. [see comment]. New England Journal of Medicine 336 17 (1997) 1202-1207
84. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine 140 2 (2004) 85-93
85. Palladini G., Perfetti V., Perlini S., et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105 7 (2005) 2949-2951
86. Zangari M., Barlogie B., Jacobson J., et al. Revimid 25 mg (REV 25) × 20 versus 50 mg (REV 50) × 10 q 28 days with bridging of 5 mg × 10 versus 10 mg × 5 as post-transplant salvage therapy for multiple myeloma (MM). Blood 102 11 (2003)